

Hosmer-Lemeshow test ( $\chi^2 = 9.654$ ;  $df = 8$ ;  $p = 0.290$ ) indicated the goodness-of-fit of the prediction model.

**Conclusions:** A previous history of depression and EPDS  $\geq 10$  in the immediate postpartum allow to identify women with high risk of PPD before leaving the Obstetric Ward.

This study has been supported in part by grants: Instituto Carlos III: GO3/184; FIS: PI041783 and FIS 05/2565.

## P058

Trazodone in the treatment of the depressed patient with insomnia

J. Martinovic, A. Miljatovic, L. Trikos. *Center of Psychiatry, University Clinical Center, Belgrade, Serbia*

**Objective:** The aim of our study: to evaluate the efficacy of trazodone in the treatment of patients with depression showing marked insomnia.

**Method:** 45 patients, with diagnosis F32.0 -F32.2 (according to ICD -10) with marked insomnia, aged 29- 64 years, were enrolled. Patients received trazodone 150 mg/day, 6 weeks, without concomitant medication. The visits were organized at the beginning of treatment, after 2, and after 6 weeks of treatment for all the patients. The Montgomery Asberg Depression Rating Scale was used as a rating instrument. Gathered data were statistically processed.

**Results:** There was a significant improvement for trazodone treated patients in the MADRS item 4 scores at weeks 2 and 6 versus baseline ( $p < 0.05$ ). They also showed significant and clinically relevant improvement in MADRS total scores after trazodone treatment.

**Conclusion:** Trazodone shows a significant beneficial effect in reducing sleep disturbance in depressed patients.

## P059

Relationship of socio-demographic characteristics of seizure types in epileptics with depression present as comorbid condition

E. Mehmedika-Suljic<sup>1</sup>, A. Alajbegovic<sup>1</sup>, N. Loncarevic<sup>1</sup>, A. Kulenovic<sup>1</sup>, Dzubur<sup>1</sup>, A. Bravo<sup>1</sup>, S. Alajbegovic<sup>2</sup>, A. Kucukalic<sup>3</sup>. <sup>1</sup>Neurology Clinic, Clinical Center, University of Sarajevo, Sarajevo, Bosnia-Herzegovina <sup>2</sup>Cantonal Hospital Zenica, Sarajevo, Bosnia-Herzegovina <sup>3</sup>Psychiatry Clinic, Clinical Center, University of Sarajevo, Sarajevo, Bosnia-Herzegovina

**Introduction:** The most common psychical disorder which occurs with epilepsy is interictal epilepsy which life prevalence is 40%-60%.

**Aim:** To establish the frequency of depressive disorder in epileptic patients taking into account socio-demographic characteristics and the type of epileptic seizures.

**Material and Methods:** The survey comprised randomly chosen 476 patients treated at the Dispensary for epilepsy at the Neurology Clinic, University Clinical Center Sarajevo. All patients were tested with MMSE, Beck and Hamilton depression tests.

**Results:** In the surveyed sample males were represented with 53.4%, mean age 36.7 years and  $SD = 12.58$ , while mean age in females was 33.3% and  $SD = 12.58$ . 80% of patients had high school education. Male patients had significantly higher rate of marriage and employment than women ( $p < 0.001$ ). Two thirds of patients had partial seizures with or without secondary generalization. Out of that number women had significantly more frequent seizures with partial complex symptoms. Depressive disorder was present in 34% of patients at the Beck scale and 38.8% at the Hamilton scale, significantly more frequent in women.

**Conclusion:** Depressive disorder was significantly more present in middle-aged women, predominantly in women with high school education, unmarried, unemployed, with significantly more frequent seizures with partial complex symptoms than males.

## P060

Anxiety and depression of patients with diabetes

K. Michelidakis<sup>2</sup>, J. Myriokefalitakis<sup>3</sup>, S. Bousboulas<sup>1</sup>, C. Istikoglou<sup>2</sup>, O. Mikirditsian<sup>2</sup>, T. Nikolaou<sup>2</sup>, M. Stathaki<sup>2</sup>, D. Vlissides<sup>2</sup>. <sup>1</sup>3rd Department of Internal Medicine, GHNP, Athens, Greece <sup>2</sup>Department of Psychiatry, Asklepeion of Voula, Athens, Greece <sup>3</sup>Department of Rheumatology, Asklepeion of Voula, Athens, Greece

There are numerous of mechanisms by which psychological dysfunction follows physical illness. They include the disturbing subjective meaning of the illness and its manifestations for the patient, impairment of the patient's capacity to cope with the needs and goals, impairment of ability to meet the demands of sexual, social and economic roles.

Symptoms of depression frequently occur in patients with diabetes and depression in the medically ill frequently goes undetected and untreated. The presence of depression is particularly problematic because depression is often associated with somatic symptoms that overlap with or resemble symptoms of diabetes. The challenge of diagnosing depression in diabetic patients is complicated by neurovegetative symptoms.

These patients resist the notion of emotional distress, substituting in its place various physical complaints.

The aims of the present study are to explore the psychopathology that occurs in patients with diabetes to study in depth their psychiatric profile.

Sixty patients mean age 61.6  $SD = 17.01$  suffered from Diabetes. There was a comparison group of sixty healthy volunteers.

The psychometric measurements employed were:

Hostility was examined by the hostility and direction of hostility questionnaire [HDHQ].

Psychiatric symptomatology was evaluated by the symptom – check-list-90-R [SCL-90-R] and the Delusions Symptoms Inventory / State of Anxiety and Depression, [DSSI / SAD].

The Diabetes patients reported significantly more symptoms of Somatization than the non-patients.

The patients with diabetes show significantly higher levels of paranoid hostility and Criticism of others.

The diabetes patients show significantly higher levels of introverted extroverted and total hostility than the healthy.

## P061

Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia

S. Montgomery<sup>1</sup>, G. Kinrys<sup>2</sup>, A. Krystal<sup>3</sup>, W.V. McCall<sup>4</sup>, T. Roth<sup>5</sup>, R. Rubens<sup>6</sup>, K. Schaefer<sup>6</sup>, J. Roach<sup>6</sup>, H. Huang<sup>6</sup>, R. Krishnan<sup>4</sup>, M. Pollack<sup>7</sup>. <sup>1</sup>Imperial College, London University, London, United Kingdom <sup>2</sup>Cambridge Health Alliance & Harvard Medical School, Boston, MA, USA <sup>3</sup>Duke University Medical Center, Durham, NC, USA <sup>4</sup>Wake Forest University Health Sciences, Winston-Salem, NC, USA <sup>5</sup>Henry Ford Sleep Disorders Center, Detroit, MI, USA <sup>6</sup>Sepracor Inc., Marlborough, MA, USA <sup>7</sup>Massachusetts General Hospital, Boston, MA, USA

**Background:** We evaluated the efficacy of eszopiclone (ESZ) and concurrent escitalopram oxalate (EO) in patients with insomnia and co-morbid GAD.

**Methods:** Patients meeting DSM-IV-TR criteria for GAD and insomnia received 10 weeks of EO 10mg and co-therapy with ESZ 3mg or placebo (PBO) for 8 weeks. For the last 2 weeks, ESZ was replaced with single-blind PBO to evaluate discontinuation effects. Sleep, daytime functioning and anxiety measures were captured during the study.

**Results:** ESZ+EO improved sleep and daytime functioning at each week and the double-blind period average ( $p < 0.05$ ). At Week 8, significantly more ESZ+EO patients had no clinically meaningful insomnia based on ISI  $\leq 7$ . Significant improvements with ESZ+EO (relative to PBO+EO) were observed in HAM-A total scores each week, and Weeks 4–10 excluding the insomnia item. ESZ+EO was significantly better at every timepoint on CGI-I ( $p < 0.02$ ); CGI-S was not different between treatments after Week 1. Median time to anxiolytic response was reduced with ESZ+EO based on HAM-A and CGI-I. HAM-A response and remission rates at Week 8 were higher with ESZ+EO, and HAM-D17 scores were improved at all timepoints ( $p < 0.004$ ). After eszopiclone discontinuation, there was no evidence of rebound insomnia, and no treatment differences in sleep or daytime function. Significant treatment differences in anxiety and mood were maintained after discontinuation.

**Conclusion:** In this study, ESZ+EO was well tolerated and associated with improved sleep and daytime function without evidence of tolerance. Improvements in anxiety and mood were observed with ESZ+EO.

Support for this study provided by Sepracor Inc., Marlborough, MA.

## P062

Prevalence, incidence and risk of depression in the Spanish cohort within the predict study

B. Moreno<sup>1</sup>, C. Montón<sup>2</sup>, M.J. Gil De Gómez<sup>3</sup>, M. Sánchez-Celaya<sup>4</sup>, B. Oliván<sup>2</sup>, M.S. Sánchez<sup>5</sup>. <sup>1</sup>Departamento de Psiquiatría, Universidad de Granada, Granada, Spain <sup>2</sup>Centro de Salud Casablanca, Zaragoza, Spain <sup>3</sup>Complejo Hospitalario San Millán-San Pedro, Logroño, Spain <sup>4</sup>Docente de Medicina Familiar Y Comunitaria, Area I, Madrid, Spain <sup>5</sup>Centro de Salud, Madrid, Spain

**Background:** Depression occurs in a quarter of general practice attendees, relapse is frequent five to 10 years from first presentation and residual disability is common. Estimating overall risk across a range of putative risk factors is fundamental to prevention of depression.

**Methods:** This is a prospective study. As part of the European Predict study, in Málaga (Spain), 9 general practices were recruited. Consecutive attendees aged 18 to 75 were recruited and undertook a detailed interview. Subjects were administered the Composite International Diagnostic Interview (CIDI) depression subscale allowing diagnoses using ICD-10 criteria for depressive episode. For risk factors the interviews included individual-level risk factors and environmental risk factors. All participants completed baseline and follow up assessments at six and 12 months.

**Results:** A total of 1276 patients were interviewed in the first assessment of the PREDICT study, in Málaga, (Spain) and the response rate of the study one year later was 88%. Out of 1276, 70.5% of the sample is women whilst only 29.5% were men. The sample's mean age was 49 years (SD=15.3). Depression was common amongst

this sample of primary care attendees, although point prevalence values varied slightly according to the diagnostic criteria used. The prevalence of ICD-10 Depressive Episode was 38.2% while ICD-10 depressive episode of mild was 3.4% moderate 12% and severe intensity 22.8%.

**Conclusions:** The high prevalence we found shows that the depressive disorders are a very common problem with the primary care attendees in our area.

## P063

Refractory pain—depression syndrome treated with tianeptine

P.S. Muniz<sup>1</sup>, A.E. Nardi<sup>2</sup>. <sup>1</sup>Palliative Care Unit, National Cancer Institute, Rio de Janeiro, Brazil <sup>2</sup>Psychiatry Institute, Federal University, Rio de Janeiro, Brazil

Chronic pain is strongly associated with anxiety and depression symptoms in advanced cancer patients. The comorbidity of pain and depression significantly difficulties symptom control and seems to create a noxious feedback mechanism in which: CHRONIC PAIN > DEPRESSION > more PAIN > DEPRESSION. We call this feedback circle as Pain-Depression Syndrome. Mr RA, is a 68-years-old male Caucasian. At the age of 66 an advanced prostatic adenocarcinoma was diagnosed. Bone metastases were concomitantly found. A mild bone pain was treated with tenoxicam 20 mg/day. The pain became more severe. We initially treated the pain with 400 mg/day of tramadol with partial response. A decision to start morphine was discussed. The patient had no history of mental disorder and his family had no history of mood or anxiety disorder. He was examined by a psychiatrist who diagnosed a major depressive episode (DSM-IV-TR) associated with chronic pain syndrome (Clinical Global Impression-GGI, severity = 5). He was prescribed with amitriptyline starting with 25 mg/day and increasing up to 75 mg/day, at which dose he experienced severe anticholinergic side effects and mild confusion. Then amitriptyline was thus halted, and he was prescribed with tianeptine 12.5 mg three times a day. After a 2 week period he described a remarkable improvement of pain control (7–3 on a analogue visual scale of pain), mood, anxiety and depressive symptoms were also improved (CGI severity = 2; CGI improvement = 1). At 6 months follow-up he had very mild pain complaints and no significant mood or anxiety symptoms.

## P064

Two years of maintenance treatment with venlafaxine xr 75–225 mg/d: Efficacy in patients with recurrent unipolar major depression

J.H. Kocsis<sup>1</sup>, S.G. Kornstein<sup>2</sup>, S. Ahmed<sup>3</sup>, T. Ferdousi<sup>3</sup>, J. Musgnung<sup>3</sup>, M. Thase<sup>4</sup>, E. Friedman<sup>4</sup>, B.W. Dunlop<sup>5</sup>, B. Yan<sup>3</sup>, R. Pedersen<sup>3</sup>, P.T. Ninan<sup>3</sup>. <sup>1</sup>Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA <sup>2</sup>Mood Disorders Institute, Virginia Commonwealth University, Richmond, VA, USA <sup>3</sup>Wyeth Pharmaceuticals, Collegeville, PA, USA <sup>4</sup>Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA <sup>5</sup>Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA

**Background:** The efficacy of venlafaxine extended-release (XR) at doses between 75 mg/d and 300 mg/d has been demonstrated in patients with recurrent major depressive disorder (MDD) over 2.5 years. This analysis evaluated the long-term efficacy of venlafaxine XR  $\leq 225$  mg/d, the approved dosage in many countries.